Loring Wolcott & Coolidge Fiduciary Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-10
| Closed | – | – | 620 |
|
|
2020
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 676 |
|
|
2020
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 728 |
|
|
2019
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 736 |
|
|
2019
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 756 |
|
|
2019
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 780 |
|
|
2019
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 784 |
|
|
2018
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 742 |
|
|
2018
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 688 |
|
|
2018
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 747 |
|
|
2018
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 806 |
|
|
2017
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 915 |
|
|
2017
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 931 |
|
|
2017
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 668 |
|
|
2017
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 635 |
|
|
2016
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 628 |
|
|
2016
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 651 |
|
|
2016
Q2 | $0 | Buy |
+10
| New | +$247 | ﹤0.01% | 657 |
|
Loring Wolcott & Coolidge Fiduciary Advisors's PTLA Position: Q3 2020 in Review
Loring Wolcott & Coolidge Fiduciary Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 10 shares.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in PTLA in Q2 2016 and held it in 17 quarters. The position peaked at $0 in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Loring Wolcott & Coolidge Fiduciary Advisors sold 10 Portola Pharmaceuticals, Inc. shares in Q3 2020.
- Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q2 2016 and held it in 17 quarters.
- Loring Wolcott & Coolidge Fiduciary Advisors's Portola Pharmaceuticals, Inc. position peaked at $0 in Q2 2020.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2020, filed 15 Oct 2020.